Skip to Content

Generic Trijardy XR Availability

Last updated on July 7, 2021.

Trijardy XR is a brand name of empagliflozin/linagliptin/metformin, approved by the FDA in the following formulation(s):

TRIJARDY XR (empagliflozin; linagliptin; metformin hydrochloride - tablet, extended release;oral)

  • Manufacturer: BOEHRINGER INGELHEIM
    Approval date: January 27, 2020
    Strength(s): 5MG;2.5MG;1GM [RLD], 10MG;5MG;1GM [RLD], 12.5MG;2.5MG;1GM [RLD], 25MG;5MG;1GM [RLD]

Has a generic version of Trijardy XR been approved?

No. There is currently no therapeutically equivalent version of Trijardy XR available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trijardy XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
    Patent 10,022,379
    Issued: July 17, 2018
    Assignee(s): Boehringer Ingelheim International GmbH

    The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

    Patent expiration dates:

    • April 2, 2029
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
      ✓ 
      Drug product
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent 10,258,637
    Issued: April 16, 2019
    Assignee(s): Boehringer Ingelheim International GmbH

    The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).

    Patent expiration dates:

    • April 3, 2034
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
  • Patent 10,406,172

    Patent expiration dates:

    • June 15, 2030
      ✓ 
      Patent use: METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
      ✓ 
      Drug product
  • Patent 10,596,120

    Patent expiration dates:

    • March 7, 2032
      ✓ 
      Patent use: TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
      ✓ 
      Drug product
    • March 7, 2032
      ✓ 
      Patent use: TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
      ✓ 
      Drug product
  • 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
    Patent 7,407,955
    Issued: August 5, 2008
    Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf R. H. & Tadayyon; Mohammad
    Assignee(s): Boehringer Ingelheim Pharma GmbH &#x26; Co., KG

    The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

    Patent expiration dates:

    • May 2, 2025
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
    Patent 7,579,449
    Issued: August 25, 2009
    Inventor(s): Eckhardt; Matthias & Eickelmann; Peter & Himmelsbach; Frank & Barsoumian; Edward Leon & Thomas; Leo
    Assignee(s): Boehringer Ingelheim International GmbH

    Glucopyranosyl-substituted benzene derivatives of general formula I where the groups R1 to R6 as well as R7a, R7b, R7c are defined herein and the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.

    Patent expiration dates:

    • August 1, 2028
      ✓ 
      Drug substance
  • Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
    Patent 7,713,938
    Issued: May 11, 2010
    Inventor(s): Himmelsbach; Frank & Schmid; Sandra & Schuehle; Martin & Martin; Hans-J&#xfc;rgen & Eckhardt; Matthias
    Assignee(s): Boehringer Ingelheim International GmbH

    The invention relates to a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S) -tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.

    Patent expiration dates:

    • April 15, 2027
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
    Patent 8,119,648
    Issued: February 21, 2012
    Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf
    Assignee(s): Boehringer Ingelheim Pharma GmbH &#x26; Co. KG

    The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

    Patent expiration dates:

    • August 12, 2023
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
  • 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
    Patent 8,178,541
    Issued: May 15, 2012
    Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf & Tadayyon; Mohammad
    Assignee(s): Boehringer Ingelheim Pharma GmbH &#x26; Co. KG

    The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

    Patent expiration dates:

    • August 12, 2023
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
      ✓ 
      Drug product
  • Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
    Patent 8,551,957
    Issued: October 8, 2013
    Assignee(s): Boehringer Ingelheim International GmbH

    The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

    Patent expiration dates:

    • October 14, 2029
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
      ✓ 
      Drug product
  • Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
    Patent 8,883,805
    Issued: November 11, 2014
    Assignee(s): Boehringer Ingelheim International GmbH

    The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.

    Patent expiration dates:

    • November 26, 2025
      ✓ 
      Drug product
  • DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
    Patent 9,155,705
    Issued: October 13, 2015
    Assignee(s): Boehringer Ingelheim International GmbH

    The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

    Patent expiration dates:

    • May 21, 2030
      ✓ 
      Drug product
  • DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
    Patent 9,415,016
    Issued: August 16, 2016
    Assignee(s): Boehringer Ingelheim International GmbH

    The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

    Patent expiration dates:

    • April 2, 2029
      ✓ 
      Drug product
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent 9,949,998
    Issued: April 24, 2018
    Assignee(s): Boehringer Ingelheim International GmbH

    The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).

    Patent expiration dates:

    • June 11, 2034
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN

More about Trijardy XR (empagliflozin / linagliptin / metformin)

Consumer resources

Professional resources

Related treatment guides

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.